In CHOL, we revealed that XPO1 inhibitor KPT‐330 could trigger the nuclear accumulation of the p53 protein and in this way significantly disrupted the proliferation of cholangiocarcinoma cells. The gene discussed is XPO1; the disease is cholangiocarcinoma.